Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 10,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the sale, the insider now directly owns 134,021 shares of the company’s stock, valued at approximately $2,189,903.14. The trade was a 6.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Down 8.0 %

Shares of CNTA opened at $14.54 on Thursday. The firm has a 50 day simple moving average of $16.49 and a two-hundred day simple moving average of $16.42. The company has a market cap of $1.92 billion, a P/E ratio of -9.50 and a beta of 1.54. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. Research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. GAMMA Investing LLC lifted its stake in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares during the last quarter. Barclays PLC lifted its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $162,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth $171,000. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

CNTA has been the topic of several recent research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim reiterated a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday. Finally, TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.